Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Abintra is a specialized nutritional supplement, classified as a medical food, designed to support the metabolic demands of wound healing in patients with chronic or non-healing wounds. Developed by Abbott Nutrition, the formulation provides high concentrations of L-arginine and L-glutamine, amino acids that serve as critical precursors for collagen synthesis, cellular proliferation, and immune function. The product also contains a blend of antioxidant vitamins (C and E) and minerals (Zinc, Copper, Selenium) that act as cofactors for enzymatic reactions essential to tissue repair and protect against oxidative stress at the wound site. It is primarily indicated for the dietary management of pressure ulcers, diabetic foot ulcers, venous leg ulcers, and surgical wounds, and is typically administered as an oral solution reconstituted from powder.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Abintra.